These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 23104468)

  • 1. Host factors determining the efficacy of hepatitis C treatment.
    Chuang WL; Yu ML
    J Gastroenterol; 2013 Jan; 48(1):22-30. PubMed ID: 23104468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.
    Jung YK; Kim JH; Ahn SM; Yang JW; Park SJ; Kim JW; Yeon JE; Kwon OS; Kim YS; Choi DJ; Kim JH; Byun KS
    J Clin Gastroenterol; 2013 Aug; 47(7):644-50. PubMed ID: 23442843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population.
    Dong ZX; Zhou HJ; Xiang XG; Guo SM; Zhuang Y; Zhao GD; Xie Q
    J Dig Dis; 2015 Feb; 16(2):90-7. PubMed ID: 25312023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.
    Shi KQ; Liu WY; Lin XF; Fan YC; Chen YP; Zheng MH
    Gene; 2012 Oct; 507(1):27-35. PubMed ID: 22842190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.
    Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Hsu SJ; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2012; 17(3):477-84. PubMed ID: 22301466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
    Chen MY; Liu CH; Chen TC; Su TH; Chen PJ; Chen DS; Kao JH; Liu CJ
    J Gastroenterol Hepatol; 2014 Jan; 29(1):102-9. PubMed ID: 23829453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C.
    Jeong SH; Jung YK; Yang JW; Park SJ; Kim JW; Kwon OS; Kim YS; Choi DJ; Kim JH
    Clin Mol Hepatol; 2012 Dec; 18(4):360-7. PubMed ID: 23323251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients younger than forty years old with hepatitis C virus genotype-1 chronic infection had treatment responses similar to genotype-2 infection and not related to interleukin-28B polymorphism.
    Lin CY; Sheen IS; Jeng WJ; Huang CW; Huang CH; Chen JY
    Ann Hepatol; 2013; 12(1):62-9. PubMed ID: 23293195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b.
    Tsubota A; Shimada N; Atsukawa M; Abe H; Kato K; Ika M; Matsudaira H; Nagatsuma K; Matsuura T; Aizawa Y
    J Gastroenterol Hepatol; 2014 Jan; 29(1):144-50. PubMed ID: 24117654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
    PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?
    Garcia RF; Moreira S; de Araújo Ramos AL; Ferreira LE; de Mattos AA; Tovo CV; Nader LA; Ramos JA; Rondinelli E; de Jesus Dominici A; Garcia CE; de Souza Leite Pinho M; Brandão-Mello CE; Villela-Nogueira CA; de França PH
    World J Gastroenterol; 2013 Nov; 19(42):7399-404. PubMed ID: 24259970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.
    Shimada N; Toyoda H; Tsubota A; Ide T; Takaguchi K; Kato K; Kondoh M; Matsuyama K; Kumada T; Sata M
    J Gastroenterol; 2014 Nov; 49(11):1485-94. PubMed ID: 24287582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients.
    El Awady MK; Bader El Din NG; Tabll A; El Hosary Y; Abdel Aziz AO; El Khayat H; Salama M; Abdelhafez TH
    World J Gastroenterol; 2013 Jan; 19(2):290-8. PubMed ID: 23345953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.
    Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
    Liver Int; 2011 Oct; 31(9):1359-65. PubMed ID: 21745312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.
    Lin CY; Chen JY; Lin TN; Jeng WJ; Huang CH; Huang CW; Chang SW; Sheen IS
    PLoS One; 2011 Mar; 6(3):e18322. PubMed ID: 21479134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis.
    Bota S; Sporea I; Şirli R; Neghină AM; Popescu A; Străin M
    Clin Drug Investig; 2013 May; 33(5):325-31. PubMed ID: 23532802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C.
    Petta S; Rosso C; Leung R; Abate ML; Booth D; Salomone F; Gambino R; Rizzetto M; Caviglia P; Smedile A; Grimaudo S; Cammà C; Craxì A; George J; Bugianesi E
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):311-7.e1. PubMed ID: 23220171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative role of vitamin D related and Interleukin-28B genes polymorphism in predicting treatment outcomes of Chronic Hepatitis C.
    El-Derany MO; Hamdy NM; Al-Ansari NL; El-Mesallamy HO
    BMC Gastroenterol; 2016 Feb; 16():19. PubMed ID: 26911666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.